A Versatile Bifunctional Chelate for Radiolabeling Humanized Anti-CEA Antibody with In-111 and Cu-64 at Either Thiol or Amino Groups: PET Imaging Of CEA-Positive Tumors with Whole Antibodies
- 8 November 2007
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 19 (1), 89-96
- https://doi.org/10.1021/bc700161p
Abstract
Radiolabeled anti-carcinoembryonic antigen (CEA) antibodies have the potential to give excellent images of a wide variety of human tumors, including tumors of the colon, breast, lung, and medullar thyroid. In order to realize the goals of routine and repetitive clinical imaging with anti-CEA antibodies, it is necessary that the antibodies have a high affinity for CEA, low cross reactivity and uptake in normal tissues, and low immunogenicity. The humanized anti-CEA antibody hT84.66-M5A (M5A) fulfills these criteria with an affinity constant of >1010 M−1, no reactivity with CEA cross-reacting antigens found in normal tissues, and >90% human protein sequence. A further requirement for routine clinical use of radiolabeled antibodies is a versatile method of radiolabeling that allows the use of multiple radionuclides that differ in their radioemissions and half-lives. We describe a versatile bifunctional chelator, DO3A-VS (1,4,7-tris(carboxymethyl)-10-(vinylsulfone)-1,4,7,10-tetraazacyclododecane) that binds a range of radiometals including 111In for gamma-ray imaging and 64Cu for positron emission tomography (PET), and which can be conjugated with negligible loss of immunoreactivity either to sulfhydryls (SH) in the hinge region of lightly reduced immunoglobulins or surface lysines (NH) of immunoglobulins. Based on our correlative studies comparing the kinetics of radiolabeled anti-CEA antibodies in murine models with those in man, we predict that 64Cu-labeled intact, humanized antibodies can be used to image CEA positive tumors in the clinic.Keywords
This publication has 25 references indexed in Scilit:
- Performance of Immuno–Positron Emission Tomography with Zirconium-89-Labeled Chimeric Monoclonal Antibody U36 in the Detection of Lymph Node Metastases in Head and Neck Cancer PatientsClinical Cancer Research, 2006
- Improved Biodistribution and Radioimmunoimaging with Poly(ethylene glycol)-DOTA-Conjugated Anti-CEA DiabodyBioconjugate Chemistry, 2005
- Tailoring antibodies for radionuclide deliveryExpert Opinion on Drug Delivery, 2005
- Comparative uptakes and biodistributions of internalizing vs. noninternalizing copper-64 radioimmunoconjugates in cell and animal models of colon cancerNuclear Medicine and Biology, 2005
- Optimization of labeling and metabolite analysis of copper-64-labeled azamacrocyclic chelators by radio-LC-MSNuclear Medicine and Biology, 2005
- Humanization of the anti-CEA T84.66 antibody based on crystal structure dataProtein Engineering, Design and Selection, 2004
- Tumor Targeting of Radiometal Labeled Anti-CEA Recombinant T84.66 Diabody and T84.66 Minibody: Comparison to Radioiodinated FragmentsBioconjugate Chemistry, 2001
- Numerical Selection of Optimal Tumor Imaging Agents with Application to Engineered AntibodiesCancer Biotherapy & Radiopharmaceuticals, 2001
- Newer approaches to the radiolabeling of monoclonal antibodies by use of metal chelatesInternational Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1991
- Selective reduction and proteolysis in the hinge region of liganded and unliganded antibodies. Identical kinetics suggest lack of major conformational change in the hinge regionEuropean Journal of Immunology, 1978